Compare Enbridge Inc (ENB) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Johnson & Johnson — how do they compare? Enbridge Inc trades at $46.6 (market cap $103.38B), while Johnson & Johnson trades at $256.5 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 6× Enbridge Inc's market cap, and Enbridge Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and Johnson & Johnson for 129 Days on average.
| ENB | JNJ | |
|---|---|---|
Market Cap | $103.38B | $618.09B |
Volume | 3,684,305 | 6,050,983 |
Sector | Energy | Health |
52-Week High | $58.04 | $278.43 |
52-Week Low | $45.23 | $186.00 |
Typical Hold Time | 91 Days | 129 Days |
Enterprise Value | $185.39B | $646.37B |
Dividend Yield | 6.02% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.465, up 1.25% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly EPS beats and a 6% dividend yield. Revenue grew to $65.19B in 2025, with net income of $7.49B, though profit margins have fluctuated. Analyst consensus is mixed with a $61.63 price target, while recent news highlights its stable cash flow and expansion into renewables.
The outlook balances a high yield and growth projects against interest rate sensitivity and debt levels near 49% of assets. Upside exists if execution on the $41B backlog drives earnings, but macroeconomic pressures and technical weakness pose near-term risks for shareholders.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
